الفهرس 
CIRRHOSISOnly 14 pages are availabe for public view
 |  | from | 156 |  |  |
| | | from | 156 | | |
Abstract
Esophageal varices are porto-systemic collaterals
resulting from portal hypertension, and considered the most
lethal complication of liver cirrhosis. Kallistatin a tissue
kallikrein-binding protein and a serine proteinase inhibitor, it is
mainly formed in the liver and its serum level is diminished in
liver cirrhosis. It has anti-angiogenic, anti-oxidant, antiinflammatory and anti-tumor effects. Kallistatin level is
believed by many literature to be related to the severity of liver
disease.
This study aimed to evaluate the value of serum
Kallistatin as a non-invasive predictor of EVs.
This study was conducted in the Gastro-enterology unit,
Internal medicine department, Ain Shams University hospitals
&Theodor Bilharz Institute. 60 cirrhotic patients and 20 healthy
individuals were included.
Serum Kallistatin level was measured for all participants
using ELISA kit supplied by Cloud-Clone Corporation® USA.
Serum Kallistatin level showed significant reduction in
patients with liver cirrhosis as compared to healthy individuals.
There was also a highly significant difference between patients
with EVs and patients without EVs as regards serum Kallistatin
level. Serum level of Kallistatin had no correlation with the size
of varices or the risky signs of variceal bleeding Serum Kallistatin level showed significant correlations
with the presence of ascites, portal hypertensive gastropathy,
MELD score, portal vein diameter and synthetic liver functions.
Conclusion:
Serum level of Kallistatin is a promising noninvasive
marker for prediction of EVs in patients with HCV- related
liver cirrhosis.